Control theory: Placebo-controlled drug trials have problems. Active-controlled drug trials are not always the solution

American Journal of Bioethics

Volumn 9, Issue 9, 2009, Pages 67-69

  Golomb, Beatrice Alexandra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

ARTICLE; CONTROLLED CLINICAL TRIAL; ETHICS; EVIDENCE BASED MEDICINE; HUMAN; METHODOLOGY; SAMPLE SIZE;

CONTROLLED CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; PLACEBOS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 70449559093     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160903098424     Document Type: Article

References (20)

1. Altman, L. K. May 2, 2006. For science's gatekeepers, a credibility gap. New York Times. Available at http://www.nytimes.com/2006/05/02/health/02docs.html?r=1.
2. Bazell, R. August 15, 2006. Risky Rx: Drug maker's secret strategies. Disturbing glimpse into how marketing dupes doctors-and patients. NBC News.
3. Bero, L., Oostvogel, F., Bacchetti, P., and Lee, K. 2007. Factors associated with findings of published trials of drug-drug comparisons: Why some statins appear more efficacious than others. Public Library of Science Medicine 4: e184.
4. Bolland, M. J., Barber, P. A., Doughty, R. N. et al. 2008. Vascular events in healthy older women receiving calcium supplementation: Randomized controlled trial. British Medical Journal 336: 262-266.
5. Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., and Campos, H. 2006. Coffee, CYP1A2 genotype, and risk of myocardial infraction. Journal of American Medical Association 295: 1135-1141.
6. Criqui, M. H., and Golomb,B. A. 2004. Low and lowered cholesterol and total mortality. Journal of the American College of Cardiology 44: 1009-1010.
7. Golomb, B. A., Parrish, J., and Broadwin, J. A. 2009. Statins and mortality. On the Risk 25: 66-71.
8. Golomb, B. A. 1995a. Paradox of placebo effect. Nature 375: 530.
9. Golomb, B. A. 1995b. Are placebos bearing false witness? Chemistry and Industry 21: 900.
10. Golomb, B. A. 1996. Using placebos. Nature 379: 765.
11. Golomb, B. 2002. When are medication side effects due to the nocebo phenomenon? Journal of American Medical Association 287: 2502-2504.
12. Golomb, B. A., Dimsdale, J. E., Evans, M. A., Denenberg, J. O., White, H. L., and Criqui, M. H. 2008. Effects of statins on aggression differ by gender: Results of a double blind placebo controlled trial. Circulation Supplement 117: e268-e269.
13. Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., and Leucht, S. 2006. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry 163: 185-194.
14. Howick, J. 2009. Questioning the methodologic superiority of 'placebo' over 'active' controlledtrials. American Journal of Bioethics Neuroscience 9(9): 34-48.
15. Ross, J. S., Hill, K. P., Egilman, D. S., and Krumholz, H. M. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of American Medical Association 299: 1800-1812.
16. Smith, D. G., Song, F., and Sheldon, T. 1993. Cholesterol lowering and mortality: The importance of considering initial level of risk. British Medical Journal 306: 1367-1373.
17. Smith, R. 2005. Medical journals are an extension of the marketing arm of pharmaceutical companies. Public Library of Science Medicine 2: e138.
18. Steinman, M. A., Bero, L. A., Chren, M. M., and Landefeld, C. S. 2006. Narrative review-The promotion of gabapentin: An analysis of internal industry documents. Annals of Internal Medicine 145: 284-293.
19. Tramer, M. R., Reynolds, D. J., Moore, R. A., and McQuay, H. J. 1997. Impact of covert duplicate publications on meta-analysis: A case study. British Medical Journal 315: 635-640.
20. Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., and Rosenthal, R. 2008. Selective publication of antidepressant trialsand its influence on apparent efficacy. New England Journal of Medicine 358: 252-260.